BCHE and dementia: In moderate–severe dementia due to ad, memantine (an NMDA receptor antagonist) is frequently used which exerts moderate benefits in combination with cholinesterase inhibitors—namely a small clinical benefit in clinical global rating (−0.21), slight improvements in ADL performance, behaviour and mood (−1.84 points on the Neuro-Psychiatric Inventory) but no impact on cognitive function [77].